Literature DB >> 3116370

Inhibitory effect of capsular antigen of Vibrio vulnificus on bactericidal activity of human serum.

S Shinoda1, M Kobayashi, H Yamada, S Yoshida, M Ogawa, Y Mizuguchi.   

Abstract

Opaque (Op) and translucent (Tr) colonial variants were isolated from Vibrio vulnificus strains. Op-type variants were more resistant than the isogenic Tr-type variants, but the survival rate of the Op-type variants varied with the strains. Antisera were prepared by immunizing rabbit with whole cells of Op and Tr variants of some strains, in which the difference of the sensitivity between Op and Tr cells was remarkable. Then agglutination tests with their living and heat-killed cells were carried out. The results suggested the presence of capsular antigen in Op cells and its absence in Tr cells, with the exception of the existence of a slight amount of capsular material in Tr variants of strain L-180. The thin capsular layer of Tr cells of strain L-180 was also demonstrated electron microscopically, but the layer was thinner than that of the isogenic Op cells. Results of determination of sugar content in the extracted capsular fraction also showed that Op to Tr transformation was due to loss of capsular antigen of the cells. These results confirmed the morphological studies previously reported which suggested the prevention of host defense system by the capsular material of the vibrio.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116370     DOI: 10.1111/j.1348-0421.1987.tb03102.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  12 in total

Review 1.  Hepcidin: the missing link between hemochromatosis and infections.

Authors:  Houman Ashrafian
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  Roles of RseB, sigmaE, and DegP in virulence and phase variation of colony morphotype of Vibrio vulnificus.

Authors:  Roslyn N Brown; Paul A Gulig
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

3.  Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextran-treated mice.

Authors:  A M Starks; T R Schoeb; M L Tamplin; S Parveen; T J Doyle; P E Bomeisl; G M Escudero; P A Gulig
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor.

Authors:  Shee Eun Lee; Soo Young Kim; Choon Mee Kim; Mi-Kwang Kim; Young Ran Kim; Kwangjoon Jeong; Hwa-Ja Ryu; Youn Suhk Lee; Sun Sik Chung; Hyon E Choy; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

5.  Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus.

Authors:  A C Wright; J L Powell; J B Kaper; J G Morris
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice.

Authors:  Karen E Cerveny; Angelo DePaola; Donna H Duckworth; Paul A Gulig
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

Authors:  S J Devi; U Hayat; J L Powell; J G Morris
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

8.  The type IV leader peptidase/N-methyltransferase of Vibrio vulnificus controls factors required for adherence to HEp-2 cells and virulence in iron-overloaded mice.

Authors:  R N Paranjpye; J C Lara; J C Pepe; C M Pepe; M S Strom
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Vibrio vulnificus damages macrophages during the early phase of infection.

Authors:  Takahiro Tsuchiya; Eriko Mitsuo; Nahoko Hayashi; Yuuko Hikita; Hiroshi Nakao; Shigeo Yamamoto; Katsushiro Miyamoto; Hiroshi Tsujibo
Journal:  Infect Immun       Date:  2007-06-25       Impact factor: 3.441

10.  Immunogenicity of Vibrio vulnificus capsular polysaccharides and polysaccharide-protein conjugates.

Authors:  J G Simonson; R J Siebeling
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.